Eukaryotic mRNAs contain a 5′ cap structure that is crucial for recruitment of the translation machinery and initiation of protein synthesis. mRNA recognition is thought to require direct interactions between eukaryotic initiation factor 4E (eIF4E) and the mRNA cap. However, translation of numerous capped mRNAs remains robust during cellular stress, early development, and cell cycle progression 1 despite inactivation of eIF4E. Here we describe a cap-dependent pathway of translation initiation in human cells that relies on a previously unknown cap-binding activity of eIF3d, a subunit of the 800-kilodalton eIF3 complex. A 1.4 Å crystal structure of the eIF3d cap-binding domain reveals unexpected homology to endonucleases involved in RNA turnover, and allows modelling of cap recognition by eIF3d. eIF3d makes specific contacts with the cap, as exemplified by cap analogue competition, and these interactions are essential for assembly of translation initiation complexes on eIF3-specialized mRNAs 2 such as the cell proliferation regulator c-Jun (also known as JUN) . The c-Jun mRNA further encodes an inhibitory RNA element that blocks eIF4E recruitment, thus enforcing alternative cap recognition by eIF3d. Our results reveal a mechanism of cap-dependent translation that is independent of eIF4E, and illustrate how modular RNA elements work together to direct specialized forms of translation initiation.
| 5′ end recognition of c-Jun mRNA is eIF4F-independent. a, Distribution of c-Jun or ACTB mRNA-containing initiation complexes in programmed 293T cell in vitro translation extracts. The mRNA abundance (black line) is expressed as the fraction of total recovered transcripts. The results are given as the mean ± s.d. of a representative quantitative RT-PCR experiment performed in duplicate. The polysome profile (grey line) is plotted as relative absorbance at 254 nm versus elution fractions. b, Western blot analysis of initiation factors in 48S translation complexes formed on c-Jun and ACTB mRNAs. 293T, total protein from 293T in vitro translation extracts. rpS19, ribosomal protein S19. For gel source data, see Supplementary Fig. 1 . c, Phosphorimage of SDS-PAGE gel resolving RNase-protected 32 P-internal or 32 P-cap-labelled c-Jun 5′ UTR RNA crosslinked to eIF3 subunits. Recombinant eIF3a migrates at ~100 kDa owing to a C-terminal truncation 26 . The results of a-c are representative of three independent experiments. LETTER RESEARCH might also be involved in 5′ cap recognition. In agreement with the previously demonstrated RNA-binding capability of eIF3, the four eIF3 RNA-binding subunits, eIF3a, eIF3b, eIF3d and eIF3g, provide RNase protection to internally 32 P-labelled c-Jun 5′ UTR RNA after UV 254 -induced crosslinking 2 (Fig. 1c ). By contrast, when the 32 P label is placed in the 5′ cap of c-Jun mRNA, RNase protection is observed with a single subunit of eIF3, corresponding to eIF3d ( Fig. 1c , Extended Data Fig. 2a ). We confirmed subunit identity by limited proteolysis and mass spectrometry, and defined a C-terminal region of eIF3d that is responsible for protection of the 5′ mRNA terminus (Extended Data Fig. 2 ). The mapped C-terminal region of eIF3d is broadly conserved throughout plant, fungal and animal phylogeny ( Fig. 2a , Extended Data Fig. 3 ), suggesting the apparent 5′ end recognition activity of eIF3d is an evolutionarily preserved function of the eIF3 complex.
To understand how eIF3d recognizes the 5′ RNA terminus, we determined a 1.4 Å crystal structure of the conserved C-terminal domain of eIF3d from Nasonia vitripennis (65% identical, 84% similar to human eIF3d) using sulfur anomalous dispersion for phase determination (Extended Data Table 1 , Extended Data Fig. 3 ). The structure of eIF3d reveals a complex fold that forms a cup-shaped architecture with a positively charged central tunnel that is negatively charged at its base ( Fig. 2b) . Remarkably, despite no significant sequence homology, the structural topology of eIF3d is nearly identical to the DXO proteins, a recently described family of 5′ cap-endonucleases involved in RNA quality control [14] [15] [16] (Fig. 2c , Extended Data Fig. 4 ). In contrast to DXO, eIF3d contains a unique insertion of ~15 highly conserved amino acids between strand β5 and helix α6. The eIF3d-specific insertion folds down along the front face of the domain, making loosely packed charged interactions that close off the RNA binding tunnel (Extended Data Fig. 5 ). We term this insertion an 'RNA gate' , as the sequence clashes with the path of single-stranded RNA (ssRNA) bound to DXO 15 and must undergo a conformational change for eIF3d to become competent for RNA recognition (Fig. 2d ). We determined the structure of eIF3d in two additional crystal forms, and confirmed the RNA gate exhibits a closed conformation regardless of crystal packing (Extended Data Fig. 6 ). As eIF3d does not bind all capped RNAs 17,18 , we postulate that the RNA gate regulates cap recognition to prevent promiscuous mRNA binding before assembly of eIF3d into the full eIF3 complex. We tested this model using c-Jun mRNA, and verified that eIF3d cap-recognition only occurs in the context of a full eIF3 complex and requires previous eIF3-sequence-specific RNA interactions with the eIF3-recruitment stem-loop (Extended Data Fig. 7 ). Allosteric communication between eIF3 subunits during initial RNA recruitment likely facilitates eIF3d RNA gate opening to allow 5′ end recognition. The structure of eIF3d therefore reveals a new cap-binding protein and explains the ability of the eIF3 complex to protect the 5′ end of mRNA ( Fig. 1c) .
To validate the structural finding that eIF3d is a cap-binding protein, we examined the ability of eIF3 to bind the c-Jun mRNA 5′ cap in the presence of competitor ligands. eIF3d cap recognition is sensitive to m 7 GDP competition but resistant to GDP, indicating that, analogous to eIF4E 4 , eIF3d specifically interacts with the 5′ cap and requires a mature methylated cap structure for recognition ( Fig. 3a ). Using the DXO-RNA structure as a template 15 , we modelled a capped ssRNA along the basic binding groove shared between eIF3d and DXO and identified two conserved helices (α5 and α11) likely to be involved in cap recognition (Fig. 3b ). We purified recombinant eIF3 containing helix α5or α11-mutated eIF3d and demonstrated that both mutants have markedly reduced ability to crosslink to the c-Jun mRNA cap ( Fig. 3c ). eIF3d-mutated complexes retain wild-type-levels of RNAbinding, indicating that these residues specifically coordinate 5′ mRNA cap recognition (Extended Data Fig. 8 ). We next introduced haemagglutinin (HA) epitope-tagged wild-type or mutant eIF3d into 293T cells, and measured the assembly of 48S initiation complexes on c-Jun 19, 20 . Mutations to the predicted eIF3d cap-binding surface inhibit c-Jun mRNA incorporation into translation complexes, while the control ACTB mRNA is unaffected ( Fig. 3d , Extended Data Fig. 8 ). These results demonstrate that cap binding by eIF3d is required for efficient initiation complex formation during eIF3-specialized translation. eIF3d recognition of the 5′ cap structure provides an alternative cap-dependent translation mechanism from canonical eIF4F cap recognition. Perplexingly, when the RNA stem-loop element that recruits eIF3 to the c-Jun mRNA is deleted, translation is inhibited even though the mRNA contains a 5′ cap 2 . We proposed that an RNA element within the c-Jun mRNA blocks recruitment of the eIF4F complex. In support, the 5′ cap of c-Jun mRNA crosslinks less efficiently to purified eIF4E than that of the ACTB mRNA (Extended Data Fig. 9 ). To identify the eIF4F inhibitory element, we constructed luciferase reporters to test deletions in the c-Jun 5′ UTR (Fig. 4a ). Deletion of the 5′ 153 nucleotides, but not the initial 67 nucleotides, was sufficient to allow c-Jun mRNA translation to occur independently of the eIF3-recruitment stem-loop, suggesting that canonical cap dependent translation is no longer blocked ( Fig. 4b ). We confirmed by western blot analysis of the 48S initiation complex formed on c-Jun mRNA lacking the 5′ 153 nucleotides that the eIF4F components are now present ( Fig. 4c ).
Together, we put forth a model of a previously undiscovered capdependent translation initiation pathway controlled by eIF3d recognition of the 5′ mRNA cap ( Fig. 4d ). We postulate that encoding more than one mechanism of cap-dependent translation allows cells to control protein synthesis specifically in cellular environments in which eIF4E is inactivated. In support, c-Jun mRNA translation is resistant to treatment of cells with chemicals that activate the 4E-BPs 7,8,21 (Extended Data Fig. 1 ). As modulation of eIF4E cap-binding activity allows cells to incorporate extracellular stimuli into altered translation outputs 22 , it will be important to discover whether eIF3d activity is analogously regulated. Furthermore, our data indicates that the c-Jun mRNA encodes an additional cis-acting RNA element that blocks eIF4F to ensure translation can only occur through an eIF3-specialized pathway. RNA elements that block eIF4F recruitment may be a common theme to direct mRNAs into specific translation pathways to ensure controlled protein expression. For example, a subset of homeobox mRNAs contain an RNA element that blocks cap-dependent translation to ensure usage of an internal ribosome entry site and to allow for correct homeobox expression during embryonic development 23 . Several eIF3-specialized mRNAs encode proteins involved in the control of cell proliferation, suggesting that their translation may also require enhanced regulation 2, 24 .
While considerable advances have been made in the structural understanding of eIF3 bound to the ribosome, direct localization of eIF3d in a 48S complex remains unclear 25 . Thus, understanding how eIF3d functions and assembles within the full translation initiation complex will have important mechanistic implications in how cap recognition links to mRNA ribosomal recruitment. Our discovery of 15 . Positive charge is coloured blue, negative charge is in red, and the RNA gate is removed for clarity. c, Phosphorimage of SDS-PAGE gel resolving RNase-protected 32 P-cap-labelled c-Jun 5′ UTR RNA crosslinked to wild-type (WT) or helix α5or helix α11-mutant eIF3. Helix α5-mutant eIF3d: D249Q/V262I/ Y263A; helix α11-mutant eIF3d: T317E/N320E/H321A. d, Incorporation of c-Jun and ACTB mRNA into initiation complexes by wild-type, helix α5-, or helix α11-mutant eIF3d as measured by quantitative RT-PCR. The mRNA-ribosome association is expressed as the ratio of the quantity of mRNA transcripts to 18S rRNA and normalized to the wild-type sample. The results are representative of three independent experiments and given as the mean ± s.d. from a representative quantitative RT-PCR experiment performed in duplicate. LETTER RESEARCH METHODS Cells and transfections. Human 293T cells were maintained in DMEM (Invitrogen) supplemented with 10% FBS (Seradigm). The cells were obtained from the University of California, Berkeley, Cell Culture Facility, which authenticates cells by STR profiling and tests for mycoplasma contamination. Plasmid transfections were performed using Lipofectamine 2000 (Invitrogen), following the manufacturer's protocol, and polysome or immunoprecipitation analyses were performed at 48 h after transfection. For INK128 (Cayman Chemical) cell treatment, 293T cells were incubated with the indicated concentration of INK128 for ~14-16 h before cell lysis. Plasmids. To generate the eIF3d expression plasmids, eIF3d was amplified from human cDNA and inserted into pcDNA5/FRT. A 39-nucleotide linker followed by the HA epitope tag (YPYDVPDYA) was subsequently inserted before the eIF3d stop codon. The wild-type c-Jun 5′ UTR luciferase reporter plasmid was previously described 2 . To generate the c-Jun in vitro transcription template, the 5′ UTR, ORF and 3′ UTR were separately amplified from human cDNA and stitched together downstream of a T7 promoter by Gibson cloning into pcDNA4. The ACTB in vitro transcription template was constructed by addition of a T7 promoter during amplification of the full mRNA from human cDNA and inserted into pcDNA4. Western blot. Western blot analyses were performed using the following antibodies: anti-eIF3d (Bethyl A301-758A), anti-eIF4A1 (Cell Signaling 2490), anti-eIF4G1 (Cell Signaling 2858), anti-rpS19 (Bethyl A304-002A), anti-eIF4E (Bethyl A301-154A), anti-rpLP0 (Bethyl A302-882A), anti-HA epitope tag (Pierce 26183), anti-c-Jun (Cell Signaling 9165), anti-Hsp90 (BD Biosciences 610418), and anti-4E-BP1 (Cell Signaling 9644). In vitro RNA transcription and labelling. Unlabelled RNAs were in vitro transcribed, polyadenylated, and capped as previously described 2 . For internal radiolabelling of RNAs, in vitro transcription was performed in the presence of 0.1 μM [α-32 P]ATP, then the RNA was subsequently capped with vaccinia virus enzymes (NEB). For radiolabelling of the 5′ cap, in vitro transcribed RNAs were capped with vaccinia virus enzymes and [α-32 P]GTP. RNAs were purified by phenol-chloroform extraction and ethanol precipitation. In vitro translation. In vitro translation extracts were made from human 293T cells as previously described 21 . Lysates were nuclease-treated with 18 gel U μl −1 micrococcal nuclease (NEB) in the presence of 0.7 mM CaCl 2 for 10 min at 25 °C, and the digestion was stopped by addition of 2.24 mM EGTA. Each translation reaction contained 50% in vitro translation lysate and buffer to make the final reaction with 0.84 mM ATP, 0.21 mM GTP, 21 mM creatine phosphate (Roche), 45 U ml −1 creatine phosphokinase (Roche), 10 mM HEPES-KOH, pH 7.6, 2 mM DTT, 8 mM amino acids (Promega), 255 mM spermidine, 1 U ml −1 murine RNase inhibitor (NEB), and mRNA-specific concentrations of Mg(OAc) 2 and KOAc. The optimal magnesium and potassium levels to add were determined to be 1.5 mM Mg(OAc) 2 and 150 mM KOAc for c-Jun mRNA, and 1 mM and 150 mM KOAc for ACTB mRNA. For luciferase assays, translation reactions were incubated for 1 h at 30 °C, then luciferase activity was assayed. 48S initiation complex purification. For 48S initiation complex purification from in vitro translation reactions, 180 μl reactions were incubated in the presence of GMP-PNP for 20 min at 30 °C and centrifuged for 6 min at 12,000g at 4 °C. Lysates were purified by size-exclusion chromatography through a 1 ml column packed with Sephacryl S-400 gel filtration resin (GE Healthcare) and the elutant was centrifuged through a 10-25% (w/v) sucrose gradient by centrifugation for 3.5 h at 38,000 r.p.m. at 4 °C in a Beckman SW41 Ti rotor 27 . Fractions were collected from the top of the gradient using a peristaltic pump with a Brandel tube piercer. From the appropriate fractions, RNA was purified by phenol-chloroform extraction and ethanol precipitation and protein was precipitated with trichloroacetic acid.
For affinity purification of HA epitope-tagged eIF3d-associated 48S initiation complexes from cells, three 10 cm plates of transfected 293T cells were treated with 100 μg ml −1 cycloheximide for 5 min. Cells were washed with ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 100 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 ) with 100 μg ml −1 cycloheximide and collected in lysis buffer (20 mM HEPES-KOH pH 7.4, 150 mM KOAc, 2.5 mM Mg(OAc) 2 , 1 mM DTT, 100 μg ml −1 cycloheximide, 1% (v/v) Triton X-100). Lysates were centrifuged for 6 min at 12,000g at 4 °C and purified by S-400 size-exclusion chromatography. 80 μl of anti-HA antibody-conjugated agarose beads (Sigma) was added to the elutants, tumbled for 1.5 h at 4 °C, and beads were washed three times with lysis buffer without Triton X-100. Bound complexes were eluted twice with 100 μg ml −1 HA peptide and elutants were centrifuged and analysed the same as for the in vitro purification reactions. Quantitative real-time PCR. cDNA was reverse-transcribed from RNA using random hexamers and Superscript III (Invitrogen), following the manufacturer's protocol. Real-time PCR was performed using DyNAmo HS Sybr Green (ThermoFisher), with a 20 μl reaction volume containing 2 μl cDNA and 0.5 μM of each primer. The following oligonucleotides were used: 18S rRNA forward, 5′-GGCCCTGTAATTGGAATGAGTC-3′, 18S rRNA reverse, 5′-CCAAGA TCCAACTACGAGCTT-3′; ACTB forward, 5′-CTCTTCCAGCCTTCCTTCCT-3′, ACTB-reverse, 5′-AGCACTGTGTTGGCGTACAG-3′; c-Jun forward, 5′-TGACTGCAAAGATGGAAACG-3′, c-Jun reverse; 5′-CAGGGTCATGCT CTGTTTCA-3′. eIF3-RNA crosslinking and gel shift. Recombinant eIF3 was expressed and purified from Escherichia coli as previously described 26 . For each crosslinking reaction, 1 μl water, 1 μl 125 nM labelled RNA, 1 μl 10 μg ml −1 heparan sulfate (Sigma), 1 μl 5× binding buffer (125 mM Tris-HCl, pH 7.5, 25 mM Mg(OAc) 2 , 350 mM KCl, 0.5 mM CaCl 2 , 0.5 mg ml −1 BSA, 10 mM TCEP), and 1 μl 1.5 μM purified eIF3 were added, in the listed order, and incubated for 30 min at 25 °C. For competition experiments, the water was substituted with 1 μl of 1 mM m 7 GDP/Mg 2+ or GDP/ Mg 2+ . UV 254 -induced crosslinking was performed using a short-wave UV lamp placed ~4 cm above the samples on ice for 10 min. After treatment with RNase for 10 min at 37 °C, proteins were separated by 12% SDS-PAGE, the gel was dried, and imaged using a phosphorimager. For digestion of internal labelled RNA, 2.5 U benzonase (Novagen) and 250 U RNase T1 (ThermoFisher) were used; for digestion of cap labelled RNA, 4 U RNase R (Epicentre) and 1 U RiboShredder (Epicentre) were used. For eIF3d subunit identification, after RNase treatment, samples were denatured and immunoprecipitation was performed as previously described 2 . For limited proteolysis, after RNase treatment, the reactions were treated with 2 or 20 μg ml −1 sequencing grade trypsin (Promega) for 30 min at 25 °C, before gel electrophoresis. Mass spectrometry samples were prepared as previously described 2 . Gel-shift assays were performed as previously described, using 50 nM labelled c-Jun stem-loop RNA and 300 nM purified eIF3 (ref. 2) . Recombinant eIF3d protein purification. Candidate eIF3d cap-binding domain fragments were amplified by PCR and cloned into a modified pET vector to express an N-terminal 6× His (KSSHHHHHHGSS)-MBP-TEV fusion protein as previously described 28 . Extensive expression trials were conducted to determine optimal N-and C-terminal domain boundaries and identified a minimal stable human cap-binding domain S161-F527. Recombinant protein was expressed in BL21-RIL DE3 E. coli cells co-transformed with a pRARE2 tRNA plasmid (Agilent). E. coli was grown in 2× YT media at 37 °C to an OD 600 of ~0.5, cooled at 4 °C for 15 min, induced with addition of 0.5 mM IPTG and then incubated with shaking for ~20 h at 16 °C. Pelleted cells were washed with PBS and then lysed by sonication in lysis buffer (20 mM HEPES-KOH pH 7.5, 400 mM NaCl, 10% glycerol, 30 mM imidazole, 1 mM TCEP) in the presence of EDTA-free Complete Protease Inhibitor (Roche). Following centrifugation for 30 min at 23,000g and 4 °C, clarified lysate was incubated with Ni-NTA agarose resin (QIAGEN) for 1 h at 4 °C with gentle rocking. Resin was washed with lysis buffer supplemented to 1 M NaCl and eluted by gravity-flow chromatography at 4 °C with lysis buffer supplemented to 300 mM imidazole. The eluted fraction was diluted to ~50 mM imidazole and 5% glycerol, concentrated to ~50 mg ml −1 and incubated with Tobacco Etch Virus protease for ~12 h at 4 °C to remove the MBP tag. Recombinant eIF3d was isolated from free MBP by diluting with gel-filtration buffer (20 mM HEPES-KOH pH 7.5, 250 mM KCl, 1 mM TCEP) and passing over a 5 ml Ni-NTA column (QIAGEN) connected in line with a 5 ml MBP-Trap column (GE Life Sciences) before additional purification by size-exclusion chromatography on a Superdex 75 16/60 column. Final purified eIF3d was concentrated to ~20-50 mg ml −1 , used immediately for crystallography, or flash frozen in liquid nitrogen for storage at −80 °C. Crystallization and structure determination. Initial crystals of human eIF3d were grown at 18 °C by hanging drop vapour diffusion, but diffracted poorly. Analogous eIF3d cap-binding domain sequences were cloned from a panel of highly homologous animal sequences, with the equivalent domain from the parasitic wasp N. vitripennis (S172-F537) producing the best crystals. Optimized N. vitripennis eIF3d crystals were grown in 2 μl hanging drops set at a 1:1 ratio over 300 μl of reservoir liquid: 200 mM (NH 4 ) 2 SO 4 , 100 mM Bis-Tris 6.5, 23-27% PEG-3350 (crystal form 1), 1.6-1.8 M ammonium citrate, pH 7.0 (crystal form 2), or 200 mM NaCl, 100 mM Tris 8.5, 25% PEG-3350 (crystal form 3). eIF3d crystals (crystal forms 1 and 2) were cryoprotected by covering the drop with a layer of saturated paratone-N or NVH oil (Hampton) and crystals were transferred into the oil emersion and cleaned using a Kozak cat whisker as previously described 29 , or cryoprotected by transferring to a reservoir solution supplemented with 20% ethylene glycol (crystal form 3). Crystals were harvested with a nylon loop and then flash-frozen in liquid nitrogen. X-ray diffraction data were collected under cryogenic conditions at the Lawrence Berkeley National Laboratory Advanced Light Source (beamline 8.3.1).
Data were processed with XDS and AIMLESS 30 using the SSRL autoxds script (A. Gonzalez, Stanford SSRL). eIF3d crystals belonged to the orthorhombic space group P2 1 2 1 2 1 , and contained either two copies per asymmetric unit (crystal form 1) or one copy (crystal form 2), or the space group P2 1 and contained two copies per asymmetric unit (crystal form 3). Experimental phase information was collected from a native crystal using sulfur single-wavelength anomalous dispersion. Data were collected at a minimal accessible wavelength (~7,235 eV) and iterative data sets were completed and merged from independent portions of an exceptionally large eIF3d crystal. After ~90× multiplicity, anomalous signal was detected to ~2.4 Å, and a clear phase solution was obtained at ~120× multiplicity. 35 sites were identified with HySS in PHENIX 31 corresponding to 32 sulfur atoms in eIF3d and 3 chloride positions. Phases were extended to the native eIF3d data set processed to ~1.40 Å using SOLVE/RESOLVE 32 , and model building was completed in Coot 33 before refinement with PHENIX. X-ray data for refinement were extended according to an I/σ resolution cut-off of ~1.5, CC* correlation and R pim parameters, and visual inspection of the resulting map 34 . A completed eIF3d cap-binding domain from crystal form 1 was used as a search model to determine phases for crystal form 2 and 3 using molecular replacement. Final structures were refined to stereochemistry statistics for Ramachandran plot (favoured/allowed), rotamer outliers, and MolProbity score as follows: crystal form 1, 96.8%/3.2%, 0.2% and 1.40; crystal form 2, 97.3%/2.7%, 0% and 1.29; crystal form 3 97.4%/2.6%, 0.9% and 1.26. Recombinant eIF4E protein purification and RNA crosslinking. Full-length human eIF4E was cloned and expressed using the same protocol as for eIF3d. eIF4E-RNA crosslinking was performed as described for eIF3-RNA crosslinking, 
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